Welcome to Multibagg AI
Log in to access personalized features
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Bearish
5
Neutral
7
Bullish
2
Bearish
18
Neutral
7
Bullish
21
Bearish
13
Neutral
0
Bullish
19
Discovery themes featuring this stock
Divi's Laboratories Limited is a vertically integrated pharmaceutical manufacturer and CDMO that produces Active Pharmaceutical Ingredients, intermediates, peptide fragments and nutraceutical ingredients, selling into over 100 countries with a dominant export mix and multi-site manufacturing footprint focused on generics, custom synthesis and nutraceuticals.
Financially, Q3 FY26 consolidated total income was ₹2,692 crore versus ₹2,401 crore year-ago, with profit before exceptional item and tax at ₹854 crore and reported profit after tax of ₹583 crore; nine-month revenue rose to ₹8,081 crore with constant-currency growth of 8.6% and material consumption improving from prior-year levels.
Product and geography mix is notable: exports comprise roughly 89% of sales with Europe and the United States contributing approximately 73% of exports, while product mix in Q3 was ~43% generics and ~57% custom synthesis and nutraceuticals contributed ₹214 crore in the quarter and ₹706 crore in nine months.
Operationally the company emphasises backward integration and compliance: Unit 3 at Kakinada is central to pre-chemistry supply, Unit 1 received a positive US FDA general cGMP inspection in the quarter, management is scaling peptide SPPS/LPPS capacity and advancing automation, mechanochemistry and electrochemistry to improve safety, yields and sustainability.
Pharmaceuticals & Biotechnology
Pharmaceuticals
1,76,570 Cr
Low Risk
68.8
34.1
3.1
10.5
7,077.70
5,637.50
Sales CAGR
Profit CAGR
ROE
ROCE
Discovery themes featuring this stockDivis Laboratories Ltd (DIVISLAB) is currently trading at 6,628.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Divi's Laboratories Limited is a vertically integrated pharmaceutical manufacturer and CDMO that produces Active Pharmaceutical Ingredients, intermediates, peptide fragments and nutraceutical ingredients, selling into over 100 countries with a dominant export mix and multi-site manufacturing footprint focused on generics, custom synthesis and nutraceuticals. Financially, Q3 FY26 consolidated total income was ₹2,692 crore versus ₹2,401 crore year-ago, with profit before exceptional item and tax at ₹854 crore and reported profit after tax of ₹583 crore; nine-month revenue rose to ₹8,081 crore with constant-currency growth of 8.6% and material consumption improving from prior-year levels. Product and geography mix is notable: exports comprise roughly 89% of sales with Europe and the United States contributing approximately 73% of exports, while product mix in Q3 was ~43% generics and ~57% custom synthesis and nutraceuticals contributed ₹214 crore in the quarter and ₹706 crore in nine months. Operationally the company emphasises backward integration and compliance: Unit 3 at Kakinada is central to pre-chemistry supply, Unit 1 received a positive US FDA general cGMP inspection in the quarter, management is scaling peptide SPPS/LPPS capacity and advancing automation, mechanochemistry and electrochemistry to improve safety, yields and sustainability.
Over the past 52 weeks, Divis Laboratories Ltd has traded between a low of ₹5,637.50 and a high of ₹7,077.70. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Divis Laboratories Ltd has a market capitalization of approximately 1,76,569.79. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Divis Laboratories Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 68.76 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 1,76,569.79 Cr, Divis Laboratories Ltd is classified as a Large Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Divis Laboratories Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Divis Laboratories Ltd is 68.76. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Key names listed include NTPC, Divi’s Laboratories, JK Cement, Reliance Infrastructure, Anupam Rasayan India, Dollar Industries, Polyplex Corporation, Precision Wires India, India Pesticides, Rainbow Children’s Medicare and Studds Accessories, among others.
Divi's Laboratories reported a consolidated total income of ₹2692 crores for the quarter ended December 31, 2025, marking a 12.1% increase year-on-year.
For the fiscal year ending March 31, 2025, Divi's Labs reported a 20% increase in revenue from operations to ₹9,198 crores and a 40.2% rise in standalone profit after tax to ₹2,209 crores.
The 'Biopharma Shakti' scheme, with a ₹10,000 crore outlay, is the most significant announcement. It aims to make India a global biopharma manufacturing hub, directly aligning with Divis Labs' capabilities in complex API and biologics production.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
6672.00 | 1,76,570 Cr | 68.76 | 10.53 | 0.45 | 15.32 | 19.56 | 12.82 | ||
4589.80 | 1,54,670 Cr | 72.34 | 18.44 | 0.83 | 25.49 | 13.85 | 4.82 | ||
1383.00 | 1,11,725 Cr | 28.80 | 3.24 | 0.94 | 11.27 | 14.95 | 9.11 | ||
1105.65 | 1,11,254 Cr | 22.07 | 4.10 | 0.09 | 18.59 | 17.35 | 9.59 | ||
1275.05 | 1,06,424 Cr | 25.36 | 2.81 | 0.63 | 11.07 | 12.54 | 7.15 | ||
2275.00 | 1,03,975 Cr | 19.50 | 4.63 | 0.79 | 23.76 | 24.88 | 13.96 | ||
2382.00 | 97,948 Cr | 51.20 | 6.01 | 0.04 | 11.74 | 13.13 | 6.90 | ||
| Median: 7 Co. | — | 2275.00 | 1,11,254 Cr | 28.80 | 4.63 | 0.63 | 15.32 | 14.95 | 9.11 |
Dividend TDS Guidance
Divi's Laboratories recommended a dividend of ₹30 per equity share for FY2025-26 (subject to AGM approval on Aug 10); record date Jul 24, payment on/after Aug 14; issued detailed TDS/deduction rules, documentation requirements and Jul 24 cutoff.
Dividend Tax Notice
Divi's Laboratories informed shareholders of TDS procedures for the recommended ₹30/share dividend (subject to AGM approval), record date July 24, 2026, detailing applicable withholding rates, documentation (DTAA/TRC/Form 121/Section 395) and submission deadline July 24, 2026.
